Sponsor
Revolution Medicines, Inc.
Clinical research sponsor
Clinical trials
15 shownStudy of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCNCT07777822 · lead sponsor · 2026-08-14
RECRUITINGStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsNCT07397338 · lead sponsor · 2026-01-30
RECRUITINGStudy of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsNCT07349537 · lead sponsor · 2026-01-08
RECRUITINGStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · lead sponsor · 2025-05-06
RECRUITINGStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221 · lead sponsor · 2024-01-18
RECRUITINGStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsNCT06128551 · lead sponsor · 2023-11-14
RECRUITINGStudy of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541 · lead sponsor · 2023-09-07
RECRUITINGStudy of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASNCT05379985 · lead sponsor · 2022-05-31
RECRUITINGDose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsNCT05462717 · lead sponsor · 2022-09-19
ACTIVE_NOT_RECRUITINGCombination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesNCT05054725 · lead sponsor · 2021-12-30
COMPLETEDDose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsNCT04774952 · lead sponsor · 2021-04-07
COMPLETEDDose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCNCT03989115 · lead sponsor · 2019-07-02
COMPLETEDDose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsNCT03634982 · lead sponsor · 2018-09-28
UNKNOWNStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsNCT06922591 · collaborator · 2025-05-31
RECRUITINGPhase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNCT07793253 · collaborator · 2026-11-01
NOT_YET_RECRUITINGSponsor roles
lead sponsor13
collaborator2
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.